Vivtex has secured $1.8 million in a recent funding round, providing capital to advance its innovative drug development platform. The company is focused on transforming drug development through its gastrointestinal tract organ robotic interface system (GI-ORIS™), a platform technology that enables robotic screening with fully intact and functional organs. Vivtex, currently in the preclinical stage, aims to increase the efficacy, safety, and adherence of existing and novel therapies for patients by leveraging these unique capabilities.
The GI-ORIS™ technology, originally developed in the Langer lab at MIT, represents a significant advancement in preclinical drug screening. Its ability to perform robotic screening with fully intact and functional organs offers a more physiologically relevant environment for evaluating drug candidates compared to traditional methods. This platform has diverse applications, including optimizing the oral delivery of biologics, mitigating drug toxicity, and enabling precise spatial and temporal drug delivery. Vivtex is utilizing these capabilities to develop new oral therapeutics, encompassing both reformulations of existing drugs and the creation of new chemical entities within its multiple drug development programs. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.
This capital infusion will support Vivtex's strategic growth initiatives and accelerate the progression of its preclinical drug development programs. The funding is expected to enable further research and development efforts, including expanding its scientific team and enhancing its GI-ORIS™ platform capabilities. By advancing its pipeline of novel oral therapeutics, Vivtex aims to address critical unmet needs in patient care. The company remains committed to its mission of serving patients by developing therapies that offer improved efficacy, safety, and adherence, ultimately striving to bring its innovative solutions closer to clinical application.
